Madeleine Pharmaceuticals

Madeleine Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for heart failure and related cardiorenal diseases. The company's lead program, MP-127, is a synthetic version of a naturally occurring human peptide designed to improve renal function and reduce congestion in patients with acute and chronic heart failure. By targeting natriuretic peptide receptors, Madeleine aims to provide a more effective and safer alternative to current standard-of-care diuretics and vasodilators. The company operates with a presence in both the United States and Australia, leveraging global clinical expertise to advance its pipeline of peptide-based therapeutics.